• Publications
  • Influence
A new genotype of hepatitis B virus: complete genome and phylogenetic relatedness.
The hepatitis B virus (HBV) genotype was determined in a total of 121 plasma samples collected in France and the US from patients chronically infected with HBV. HBV genotype A was predominant in thisExpand
  • 909
  • 45
Mutations in Retroviral Genes Associated with Drug Resistance
Drug resistance is the inevitable consequence of incomplete suppression of HIV replication. The rapid replication rate of HIV and its inherent genetic variation have led to the identification of manyExpand
  • 400
  • 23
  • PDF
Inhibition of the replication of hepatitis B virus in vitro by 2',3'-dideoxy-3'-thiacytidine and related analogues.
Several 2',3'-dideoxy-3'-thiapyrimidine nucleosides were studied for their ability to inhibit hepatitis B virus (HBV) DNA replication in a HBV-transfected cell line (2.2.15).Expand
  • 471
  • 16
  • PDF
Zika Virus Infects Human Placental Macrophages.
The recent Zika virus (ZIKV) outbreak in Brazil has been directly linked to increased cases of microcephaly in newborns. Current evidence indicates that ZIKV is transmitted vertically from mother toExpand
  • 275
  • 14
  • PDF
Antiviral l-Nucleosides Specific for Hepatitis B Virus Infection
ABSTRACT A unique series of simple “unnatural” nucleosides has been discovered to inhibit hepatitis B virus (HBV) replication. Through structure-activity analysis it was found that the 3′-OH group ofExpand
  • 186
  • 12
  • PDF
Characterization of human immunodeficiency viruses resistant to oxathiolane-cytosine nucleosides.
The (-) enantiomers of 2',3'-dideoxy-5-fluoro-3'-thiacytidine [(-)-FTC] and 2',3'-dideoxy-3'-thiacytidine [(-)-BCH-189] were recently shown to inhibit selectively human immunodeficiency viruses (HIV)Expand
  • 349
  • 10
  • PDF
The polymerase L528M mutation cooperates with nucleotide binding-site mutations, increasing hepatitis B virus replication and drug resistance.
  • S. Ono, N. Kato, +5 authors M. Omata
  • Biology, Medicine
  • The Journal of clinical investigation
  • 15 February 2001
After receiving lamivudine for 3 years to treat chronic hepatitis B, 67-75% of patients develop B-domain L528M, C-domain M552I, or M552V mutations in the HBV polymerase that render hepatitis B virusExpand
  • 256
  • 10
  • PDF
Towards an HBV cure: state-of-the-art and unresolved questions—report of the ANRS workshop on HBV cure
HBV infection is a major cause of liver cirrhosis and hepatocellular carcinoma. Although HBV infection can be efficiently prevented by vaccination, and treatments are available, to date there is noExpand
  • 197
  • 9
Selective inhibition of human immunodeficiency viruses by racemates and enantiomers of cis-5-fluoro-1-[2-(hydroxymethyl)-1,3-oxathiolan-5-yl]cytosine.
2',3'-Dideoxy-5-fluoro-3'-thiacytidine (FTC) has been shown to be a potent and selective compound against human immunodeficiency virus type 1 in acutely infected primary human lymphocytes. FTC isExpand
  • 269
  • 8
  • PDF
In Vitro Selection of Mutations in the Human Immunodeficiency Virus Type 1 Reverse Transcriptase That Decrease Susceptibility to (−)-β-d-Dioxolane-Guanosine and Suppress Resistance to
ABSTRACT Human immunodeficiency virus type 1 (HIV-1) isolates resistant to (−)-β-d-dioxolane-guanosine (DXG), a potent and selective nucleoside analog HIV-1 reverse transcriptase (RT) inhibitor, wereExpand
  • 93
  • 8